RVMD - Revolution Medicines Inc

https://www.revmed.com

Recent News

Analysts Raise Price Targets Following Strong Data From Revolution Medicines' Pancreatic Cancer Drug - Revolution Medicines ( NASDAQ:RVMD )

Benzinga • 3 days, 21 hours ago • score: 0.10

In 2L RAS mutant PDAC, daraxonrasib showed 35% ORR and 92% disease control with a median survival of over 13 months. First-line trials showed 47% ORR and 89% disease control, with most patients still on treatment at data cutoff. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On

Neutral

This Parker-Hannifin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Exodus Movement ( AMEX:EXOD ) , ICU Medical ( NASDAQ:ICUI )

Benzinga • 1 month ago • score: -0.02

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Wells Fargo initiated coverage on Revolution Medicines, Inc.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

52W High

$62.40

52W Low

$29.17

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.12

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-9.71

EV/Revenue (<3 favorable)

8370.02

P/S (TTM) (<3 favorable)

9035.10

P/B (<3 favorable)

4.06

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

2.01%

Institutions (25–75% balanced)

104.34%

Shares Outstanding

186,933,000

Float

158,555,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

742,000

Gross Profit (TTM)

-604,710,016

EPS (TTM)

-4.52

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.47%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.95

Momentum

Value

N/A

Trend

—

Signal Cross

No cross

As of

—